IGDCC3

Across TCGA pan-cancer cohorts, IGDCC3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGDCC3 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IGDCC3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGDCC3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

UCEC, LIHC, and PRAD are the cancer types where IGDCC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
LIHC	DFS	Median	III,IV	0.076	0.333	.003	9	view →
PRAD	DFS	Median	All	0.617	0.886	.045	6	view →
SKCM	DFS	Median	II,III,IV	0.939	0.675	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IGDCC3–UCEC (OS)

Open the UCEC breakdown →